Abstract:Background: Oxaliplatin is used in adjuvant treatment of colorectal cancer and is associated with sinusoidal obstruction syndrome. Few data are available on its effects in patients in whom portal hypertension was diagnosed before cancer treatment. Objective: Our aim was to investigate short- and long-term outcomes of surgery for colorectal cancer in patients with portal hypertension with or without cirrhosis, particularly regarding effects of adjuvant chemotherapy with oxaliplatin. Design and setting: This was a prospective cohort study performed at an academic medical center. Patients: Patients with stage II or III colorectal cancer and portal hypertension who underwent curative resection were included. Intervention: All patients received adjuvant chemotherapy with oxaliplatin (FOLFOX 4) or 5-fluorouracil and leucovorin. Main outcome measures: Potential predictive laboratory and clinical variables and postoperative (30-day) and long-term morbidity and mortality were recorded. Results: Of 63 patients enrolled, 23 (37%) had a total of 82 postoperative complications; 5 patients (8%) died within 30 days postoperatively. Univariate analysis showed that severe portal hypertension, preoperative Child class B, low albumin, the presence of ascites, preoperative upper GI tract bleeding, and high intraoperative blood loss were linked to postoperative morbidity. Presence of postoperative infection (p = 0.004), presence of preoperative ascites (p = 0.01), high intraoperative blood loss (p = 0.02), and preoperative upper GI tract bleeding (p = 0.03) were significantly related to mortality. Of 58 patients receiving adjuvant chemotherapy, 20 received the oxaliplatin regimen and 38 received 5-fluorouracil/leucovorin without oxaliplatin. The median length of follow-up was 26 (range, 6-36) months. Kaplan-Meier analyses showed that patients who received oxaliplatin had higher cumulative incidences of newly developed esophageal varices (p = 0.002), GI tract bleeding (p = 0.02), and newly formed ascites (p = 0.03). Death occurred in 8 of 20 patients (40%) in the oxaliplatin group and in 5 of 38 patients (13%) in the 5-fluorouracil group. Kaplan-Meier estimates of mean survival time were 34.4 months (95% CI, 32.4-36.5) in the 5-fluorouracil/leucovorin group vs 29.9 months (95% CI, 26-33.7) in the oxaliplatin group, and patients receiving oxaliplatin had a significantly higher relative risk of death (HR = 2.98; 95% CI, 1.03-8.65). Cancer-specific mortality was not related to treatment type. Limitations: The study was limited by the relatively small sample size and lack of randomization, which may have led to selection bias in treatment regimens. Conclusions: Colorectal cancer surgery can be done safely in portal hypertensive patients with good hepatic function; however, higher mortality is expected in patients with compromised hepatic function reserve. Compared with adjuvant chemotherapy without oxaliplatin, oxaliplatin-based chemotherapy does not significantly reduce cancer-specific mortality and may increase overall morbidity and mortality. Therefore, oxaliplatin-based chemotherapy should be used with caution in patients who have portal hypertension, even in those with good liver function.

Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer

Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer

The "appearing" and "disappearing" ascites in the treatment of colorectal cancer: a case report

Case Report: Etoposide-nedaplatin induced rhabdomyolysis in a small cell lung cancer patient

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Lower-extremity deep vein thrombosis induced by oxaliplatin and capecitabine chemotherapy: A case report

Oxaliplatin: results in colorectal carcinoma

Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan

Acute therapy-related myelodysplastic syndromes following capecitabine and oxaliplatin therapy in gastric malignant tumor: A case report

Severe Esophageal Bleeding in Colorectal Cancer Due to Antitumor Therapy: A Case Report

Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?

Misdiagnosis of severe and atypical oxaliplatin‑related hypersensitivity reaction following chemotherapy combined with PD‑1 inhibitor: A case report and literature review

Incidentally Discovered Aortic Thrombosis in a Patient Undergoing Capecitabine and Oxaliplatin Chemotherapy for Colon Cancer

Oxaliplatin-related Portal Hypertension Complicated with Esophageal Varices and Refractory Massive Ascites

Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials

Drug-induced thrombocytopenia in a patient with colorectal cancer: A case report

Oxaliplatin-based Adjuvant Chemotherapy Without Radiotherapy Can Improve the Survival of Locally-Advanced Rectal Cancer.

Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports

Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer

A review of oxaliplatin and its clinical use in colorectal cancer